Targeting of COX-2 expression by recombinant adenovirus shRNA attenuates the malignant biological behavior of breast cancer cells

Asian Pacific Journal of Cancer Prevention

Volumn 15, Issue 20, 2014, Pages 8829-8836

  Tu, Bo ^a   Ma, Ting Ting ^b   Peng, Xiao Qiong ^a   Wang, Qin ^b   Yang, Hong ^a   Huang, Xiao Ling ^a  

^a THE FIRST AFFILIATED HOSPITAL OF CHONGQING MEDICAL UNIVERSITY   (China)

^b CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

Apoptosis; Breast cancer cells; COX2 shRNA; Invasion; Proliferation; Signaling pathways

Indexed keywords

CYCLOOXYGENASE 2; MESSENGER RNA; PTGS2 PROTEIN, HUMAN; SMALL INTERFERING RNA;

ADENOVIRIDAE; APOPTOSIS; BREAST TUMOR; CELL CYCLE; CELL PROLIFERATION; CHEMISTRY; FEMALE; FLOW CYTOMETRY; GENETICS; HUMAN; METABOLISM; PATHOLOGY; PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUMOR CELL CULTURE; TUMOR INVASION; WESTERN BLOTTING;

ADENOVIRIDAE; APOPTOSIS; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL CYCLE; CELL PROLIFERATION; CYCLOOXYGENASE 2; FEMALE; FLOW CYTOMETRY; HUMANS; NEOPLASM INVASIVENESS; PHOSPHORYLATION; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED;

EID: 84911207495     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2014.15.20.8829     Document Type: Article

References (41)

1. Asara Y, Marchal JA, Carrasco E, et al (2013). Cadmium modifies the cell cycle and apoptotic profiles of human breast cancer cells treated with 5-fluorouracil. Int J Mol Sci, 14, 16600-16.
2. Bermudez Y, Yang H, Cheng JQ, et al (2008). Pyk2/ERK 1/2 mediate Sp1- and c-myc-dependent induction of telomerase activity by epidermal growth factor. Growth Factors, 26, 1-11.
3. Bresalier RS, Sandler RS, Quan H, et al (2005). Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med, 352, 1092-102.
4. Cervello M, Giannitrapani L, La Rosa M, et al (2004). Induction of apoptosis by the proteasome inhibitor MG132 in human HCC cells: Possible correlation with specific caspasedependent cleavage of β-catenin and inhibition ofbβ-cateninmediated transactivation. Int J Mol Med, 13, 741-8.
5. Charames G S, Bapat B (2006) Cyclooxygenase-2 knockdown by RNA interference in colon cancer. Int J Oncol, 28, 543-9.
6. Chen S, Qiong Y, Gardner DG, et al (2006). A role for p38 mitogenactivated protein kinase and c-myc in endothelindependent rat aortic smooth muscle cell proliferation. Hypertension, 47, 252-8.
7. Cronin-Fenton DP, Pedersen L, Lash TL, et al (2010). Prescriptions for selective cyclooxygenase-2 inhibitors, non-selective non-steroidal anti-inflammatory drugs, and risk of breast cancer in a population-based case-control study. Breast Cancer Res, 12, 15.
8. Cusimano A, Fodera D, D'Alessandro N, et al (2007). Potentiation of the antitumor effects of both selective cyclooxygenase-1 and cyclooxygenase-2 inhibitors in human hepatic cancer cells by inhibition of the MEK/ERK pathway. Cancer Biol Therapy, 6, 1461-8.
9. Daksis JI, Lu RY, Facchini LM, et al (1994). Myc induces cyclin D1 expression in the absence of denovo protein synthesis and links mitogen-stimulated signal transduction to the cell cycle. Oncogene, 9, 3635-45.
10. Dong JY, Wang Q, Liang QD, et al (2013). Construction and identification of recombinant adenovirus with COX-2-shRNA. Chin J Biologicals, 26, 1072-7.
11. Fodera D, D'Alessandro N, Cusimano A, et al (2004). Induction of apoptosis and inhibition of cell growth in human hepatocellular carcinoma cells by COX-2 inhibitors. Ann N Y Acad Sci, 1028, 440-9.
12. George C (1999). Mechanisms of apoptosis by c-myc. Oncogene, 18, 2967-87.
13. Half E, Tang XM, Gwyn K, et al (2002). Cyclooxygenase-2 expression in human breast cancers and adjacent ductal carcinoma in situ. Cancer Res, 62, 1676-81.
14. Han G, Gang W, Yan B, et al (2012). C-myc overexpression promotes osteosarcoma cell invasion via activation of MEKERK pathway. Oncol Res, 20, 149-56.
15. Harris RE, Beebe-Donk J, Doss H, et al (2005). Aspirin, ibuprofen, and other non-steroidal anti-inflammatory drugs in cancer prevention: a critical review of non-selective COX-2 blockade. Oncol Rep, 13, 559-83.
16. He TC, Zhou S, Luis T, et al (1998). A simplified system for generating recombinant adenoviruses. Medical Sciences Proc. Natl Acad Sci. 95, 2509-14.
17. Hochegger H, Takeda S, Hunt T, et al (2008). Cyclin-dependent kinases and cell cycle transitions: does one fit all? Nat Rev Mol Cell Biol, 9, 910-6.
18. Hoffman B and Liebermann DA (2008). Apoptotic signaling by c-MYC. Oncogene, 27, 6462-72.
19. Janghorban M, Farrell AS, Allen-Petersen BL, et al (2014). Targeting c-MYC by antagonizing PP2A inhibitors in breast cancer. Proc Natl Acad Sci USA, 111, 9157-62.
20. Jovanovic M, Stefanoska I, Radojcic L, et al (2010). Interleukin-8 (CXCL8) stimulates trophoblast cell migration and invasion by increasing levels of matrix metalloproteinase (MMP) 2 and MMP9 and integrins alpha5 and beta1. Reproduction. 139, 789-98.
21. Holmes MD, Chen WY, Schnitt SJ, et al (2011). COX-2 expression predicts worse breast cancer prognosis and does not modify the association with aspirin. Breast Cancer Res Treat, 130, 657-62.
22. Ferguson RD, Novosyadlyy R, Fierz Y, et al (2012). Hyperinsulinemia enhances c-Myc-mediated mammary tumor development and advances metastatic progression to the lung in a mouse model of type 2 diabetes. Breast Cancer Res, 14, 8.
23. Komatsu K, Buchanan FG, Katkuri S, et al (2005). Oncogenic potential of MEK1 in rat intestinal epithelial cells is mediated via cyclooxygenase-2. Gastroenterology, 129, 577-90.
24. Lin MT, Lee RC, Yang PC, et al (2001). Cyclooxygenase-2 inducing Mcl-1-dependent survival mechanism in human lung adenocarcinoma CL1.0 cells. Involvement of phosphatidylinositol 3-kinase/Akt pathway. J Biol Chem, 276, 48997-9002.
25. Llovet JM, Bruix J (2008). Molecular targeted therapies in hepatocellular carcinoma. Hepatol, 48, 1312-27.
26. Murata H, Kawano S, Tsuji S, et al (1999). Cyclooxygenase-2 overexpression enhances lymphatic invasion and metastasis in human gastric carcinoma. Amer J Gastroenterol, 94, 451-5.
27. Parkin DM, Bray F, Ferlay J, et al (2005). Global cancer statistics, 2002. CA Cancer J Clin, 55, 74-108.
28. Patel VA, Dunn MJ, Sorokin, et al (2002). Regulation of MDR-1 (P-glycoprotein) by cyclooxygenase-2. J Biol Chem, 277, 38915-20.
29. Schutze N (2004). siRNA technology. Mol Cell Endocrinol, 213, 115-9.
30. Shalaby MA, Nounou HA, Alanazi MS, et al (2014). Associations between single nucleotide polymorphisms of COX-2 and MMP-2 genes and colorectal cancer susceptibility in the Saudi population. Asian Pac J Cancer Prev, 15, 4989-94.
31. Shirahama T, Arima J, Akiba S, et al (2001). Relation between cyclooxygenase-2 expression and tumor invasiveness and patient survival in transitional cell carcinoma of the urinary bladder. Cancer, 92, 188-93.
32. Siegfried JM, Gubish CT, Rothstein ME, et al (2007). Signaling pathways involved in cyclooxygenase-2 induction by hepatocyte growth factor in non small-cell lung cancer. Mol Pharmacol, 72, 769-79.
33. Singh B, Berry JA, Shoher A, et al (2006). COX-2 overexpression increases motility and invasion of breast cancer cells. Int J Oncol, 26, 1393-9.
34. Singh B, Cook KR, Vincent L, et al (2011). Role of COX-2 in tumorospheres derived from a breast cancer cell line. J Surg Res, 168, 39-49.
35. Sobolewski C, Cerella C, Dicato M, et al (2010). The role of cyclooxygenase-2 in cell proliferation and cell death in human malignancies. Int J Cell Biol, 2010, 215158 (21 pages).
36. Song D, Miao Cui M, Zhao G, et al (2014). Pathway-based analysis of breast cancer. Am J Transl Res, 6, 302-11
37. Strillaeeit A, Griffoni C, Spiral E, et al (2006). RNA interference as a key to knockdown overexpressed cyclooxygenase-2 in tumor cells. Br J of Cancer, 94, 1300-10.
38. Su B, Chen S (2009). Lead optimization of COX-2 inhibitor nimesulide analogs to overcome aromatase inhibitor resistance in breast cancer cells. Bioorg Med Chem Lett, 19, 6733-5.
39. Tai WT, Cheng AL, Shiau CW, et al (2011). Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma. J Hepatol, 55, 1041-8.
40. Xia JJ, Pei LB, Zhuang JP, et al (2010). Celecoxib inhibits beta-catenin-dependent survival of the human osteosarcoma MG-63 cell line. J Int Med Res, 38, 1294-304.
41. Yamanaka Y, Shiraki K, Inoue T, et al (2006). COX-2 inhibitors sensitize human hepatocellular carcinoma cells to TRAILinduced apoptosis. Int J Mol Med, 18, 41-7.